Evaluation of serum adenosine deaminase activity and autoantibodies in systemic lupus erythematosus by Khan, Seraj Ahmed et al.
154 www.journals.viamedica.pl/medical_research_journal
ORIGINAL ARTICLE
Seraj Ahmed Khan1 , Bijaya Mishra1 , Madhab Lamsal1 , Prajwal Pandey2 , Suchana Marattha2
1Department of Biochemistry, BP Koirala Institute of Health Sciences, Dharan, Nepal
2Department of Dermatology and Venerology, BP Koirala Institute of Health Sciences, Dharan, Nepal
Evaluation of serum adenosine 
deaminase activity and autoantibodies  
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ABSTRACT
Introduction: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with no single specific 
and sensitive test available for its diagnosis. Adenosine deaminase (ADA) is an enzyme that can act as an 
indicator of cellular immunity reflecting the extent of inflammation. The aim of this study was to investigate 
the role of serum adenosine deaminase activity and its association with antinuclear antibodies (ANA) and 
anti-dsDNA (anti-double stranded deoxyribonucleic acid) in SLE patients. 
Material and methods: In this study, we included 36 diagnosed case of SLE as per the American Rheu-
matology Association (ARA) criteria and 30 healthy control. Serum ADA activity was measured by a 
spectrophotometric technique based on Giusti and Gallanti. ANA and Anti ds-DNA were measured by 
indirect Enzyme-Linked Immune Sorbent Assay (ELISA). Normal values of serum ADA activity, ANA and 
anti ds-DNA was < 25 IU/L, <1 0 U/mL and <25 IU/mL respectively. 
Results: The mean ADA activity (37.03 ± 13.03 IU/L) in SLE patients was higher as compared to control 
(18.23 ± 10.12 IU/L), and the difference was statistically significant (p < 0.001). Median values of ANA 
and anti-dsDNA in SLE patients was 16.9 (8.5, 42.8) and 24.7 (20.5, 45.0) respectively. Serum ANA was 
positive in 25 out of 36 cases, anti-dsDNA was positive in 17 out of 36 cases and ADA was positive in 
29 out of 36 cases. We observed a weak positive correlation between ANA and anti-dsDNA (r = 0.46, 
p = 0.005), whereas a moderate correlation between ANA and ADA (r = 0.525, p = 0.001) in SLE patients. 
Conclusion: Serum ADA was significantly higher in SLE patients as compared to control and more specific 
than autoantibodies. Determination of ADA activity is a reliable, cost-effective, and easy test that can be 
used as an alternative parameter for diagnosing and evaluating disease activity in SLE patients. 
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Introduction
Adenosine deaminase is a hydrolytic enzyme 
that catalyzes the conversion of adenosine to inosine 
or 2’-deoxyadenosine to 2’-deoxyadenosine and is 
widely distributed in many tissues [1]. The role of ADA 
has been widely discussed and its role in regulating 
immune response has been demonstrated experi-
mentally. Numerous evidence highlights its role in the 
function, maturation and regulation of immunological 
responses [2–5]. Impaired immune tolerance is an im-
portant characteristic of autoimmune diseases, which 
led many researchers to investigate the role of ADA in 
autoimmune disease [6, 7]. Several studies have shown 
increased ADA activity in diseases like rheumatoid ar-
thritis (RA), and SLE [8–11]. Autoimmune disease can 
be organ-specific or non-organ-specific, in which the 
body damages self-tissues [12]. SLE is a connective 
tissue disease of idiopathic origin, the spectrum of 
which covers a wide array of clinical and laboratory 
manifestations. While the etiology of SLE is thought 
to be multifactorial, the disease is characterized by 
the production of autoantibodies. SLE is a prototypic 
example of non-organ specific autoimmune disorder in 
which plethora of autoantibodies is formed especially 
against nuclear DNA. Moreover, T-cell/B-cell dysregula-
tion are an important hallmark of SLE [13, 14]. Though 
the 5-year survival rate is 90% [15], however, survival 
rate has not improved since 1980. Due to its multi-organ 
involvement of SLE no single specific test is available till 
date in making its diagnosis. Hence it becomes crucial 
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in diagnosis and monitoring disease activity. Therefore 
this study was undertaken to assess the role of serum 
ADA level in SLE patients and explore its role in the 
diagnosis of the same.
Material and methods
Study population and setting
This was a hospital-based cross-sectional study 
conducted in the Department of Biochemistry in collabo-
ration with the Department of Dermatology and Venerol-
ogy. A total of 36 diagnosed cases of SLE patients and 
30 age and sex-matched healthy control were included 
in the study. A brief interview was taken from the patient 
and control group to fill up the preformed proforma. 
Ethical clearance
The research proposal was approved by the Insti-
tutional Review Committee, of B.P. Koirala Institute of 
Health Sciences, Dharan, Nepal and was conducted 
in accordance with the Declaration of Helsinki adopted 
by the 18th World Medical Assembly, Helsinki, Finland, 
June 1964. The study was initiated only after taking the 
written informed consent from the participants.
Sample collection and analysis 
Three mL venous blood was drawn in a plain vial 
following the standard protocol. The samples were 
collected in the Immunoassay Laboratory and the 
serum was separated after centrifuging the sample for 
10 minutes at 3000 rpm. Collected serum was used 
for the analysis of ADA, ANA, anti-dsDNA and other 
biochemical parameters
Analytical procedures
Serum ADA activity: The ADA activity was measured 
at 37°C according to the method of Giusti and Galanti, 
based on the Bertholet reaction, i.e. the formation of 
colored indophenol complexes from ammonia liberated 
from adenosine, and quantified spectrophotometrically 
at 625nm. ANA and anti-dsDNA were measured by in-
direct Enzyme-Linked Immunosorbent Assay (ELISA). 
As per our Lab, normal values of serum ADA activity, 
ANA and anti-dsDNA were < 25 IU/L, < 10 U/mL 
and < 25 IU/mL respectively.
Statistical analysis
The values are expressed as mean ± SD, median 
and interquartile range for continuous variable and num-
ber and percentage for nominal variables. Normality of 
the data was tested by the Kolmogorov Smirnov test. 
Statistical analysis of differences within and between the 
study groups was carried out using the Student t-test 
and Chi-square test. Pearson’s correlation coefficients 
were used to determine the relationships between pa-
rameters. The analysis was done by Statistical Package 
for the Social Sciences (SPSS) 16.0 version software. 
P < 0.05 was considered as statistically significant.
Results
In this study, we included 36 diagnosed cases of 
SLE which were referred to the Biochemistry Labora-
tory from the Dermatology department. Thirty age and 
sex-matched healthy control were also enrolled in the 
study. Mean age of SLE patients was 34 ± 13.49 years 
whereas that of control was 36.23 ± 15.34 years and 
was not statistically significant which fulfilled the age-
matched criteria for selecting the two groups. There 
were 86% of females in SLE patients and 80% female in 
the control group and the difference was not significant. 
We did not observe any significant difference in BMI 
between the groups (p = 0.062). CRP level was quite 
high (12.8 ± 12.2 mg/dL) in SLE group as compare to 
the control (3±2.8 mg/dl) and was statistically signifi-
cant (p = 0.02). No significant difference was seen in 
Hemoglobin and ESR level among the two groups. Se-
rum ADA activity in SLE group (37.03 ± 13.03 IU/L) was 
higher as compared to control (18.35 ± 7.71 IU/L) and 
the difference was statistically significant (p < 0.001). 
The median ANA and anti-dsDNA in the SLE group was 
16.9 (8.5, 42.8) and 24.7 (20.5, 45.0), respectively. Se-
rum ANA was positive in 25 out of 36 cases, anti-dsDNA 
was positive in 17 out of 36 cases whereas ADA was 
positive in 29 out of 36 cases. A weak positive correla-
tion between ADA and anti-dsDNA (r = 0.46, p = 0.005) 
was observed whereas a moderate correlation between 
ADA and ANA (r = 0.525, p = 0.001) was observed in 
SLE patients (Fig. 1, 2).
Discussion
The exact pathophysiology of SLE is not known, 
although many etiologies like infection, genetic, immu-
nologic etc., have been described [16]. In this study, 
we investigated the ADA activity in SLE patients and 
found that its level was significantly high as compared to 
healthy control. Previous studies have also reported in-
crease serum ADA activity in various diseases, including 
infection, malignancies and liver disease [17]. Various 
studies in the past have reported high ADA activity in 
SLE patients [10, 11, 18], our results are also in accor-
dance with them. Even though the mechanism by which 
ADA activity increases has not been fully elucidated, 
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Table 1. Basic and laboratory parameter among the groups
Variables SLE patients Control P value









BMI (kg/m2) 26.2 ± 4.3 24.4 ± 3.5 0.063
Hb (g/dL) 11.3 ± 1.4 10.9 ± 0.6 0.06
ESR (mm/hr) 33.7 ± 23.5 28.1 ± 10.3 0.08
CRP (mg/L) 12.8 ± 12.2 3 ± 2.8 0.02
ADA (IU/L) 37.03 ± 13.03 18.35 ± 7.71 < 0.001
ANA (U/mL) 16.9 (8.5, 42.8) — NA
dsDNA (IU/L) 24.7(20.5,45.0) — NA
ADA — adenosine deaminase; ANA — antinuclear antibodies; BMI — body mass index; dsDNS — double-stranded deoxyribonucleic acid; SLE 
— systemic lupus erythematosus
Figure 1. Correlation between adenosine deaminase and 
antinuclear antibodies in systemic lupus erythematosus patients 
Figure 2. Correlation between adenosine deaminase and 
anti-double-stranded deoxyribonucleic acid in systemic 
lupus erythematosus patients  
possibly its increase in SLE patients can be correlated 
to altered immune response [19, 20].
As per literature review female are more prone to 
autoimmune diseases as compared to male. A similar 
finding was observed in our study as well, where 86% of 
the SLE patients were female. Laxminarayana et al. [21] 
have reported that female was having 6–10 fold higher 
chance of acquiring SLE compared to male.
At present,ANA and anti-dsDNA are an important 
parameters in the diagnosis of SLE, as per the American 
Rheumatology Association (ARA) criteria. Though many 
more criteria are included to complete the diagnosis. In 
this study serum, ANA and anti-dsDNA in SLE patients 
was also evaluated. We observed ANA was positive in 69% 
of the cases, anti-dsDNA was positive in only 47% of the 
cases whereas ADA was positive in 80% of the cases. This 
results highlight the utility of ADA in diagnosing SLE as it 
is more specific than the conventional antibodies.
Conclusion
This study concludes that serum ADA activity was 
higher in SLE patients as compared to control group and 
is more specific in diagnosing the SLE as compared to 
autoantibodies. Determination of ADA levels is a reliable, 
cost-effective and easy test that can be used as alter-
native parameters representing disease activity in SLE 
patients. However, it would be too early to conclude ADA 
as a marker of SLE, therefore, further studies with a large 
number of samples is required to generalize our findings.
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